Jürgen Geisler

This study uses whole-exome sequencing and single-cell DNA sequencing to analyze subclonal evolution in breast cancer during aromatase inhibitor treatment, identifying resistance mechanisms and actionable targets.

The paper identifies prenatal BRCA1 epimutations as a cause of approximately 20% of triple-negative breast cancers and low-ER expression breast cancers.

The paper identifies breast cancer risk variants associated with tumor subtypes and shows their differential effects on luminal and non-luminal subtypes.